Barbara Leyman - Apr 4, 2025 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
Chief Business Dev. Officer
Signature
/s/ David Pauling as attorney-in-fact for Barbara Leyman
Stock symbol
STRO
Transactions as of
Apr 4, 2025
Transactions value $
$0
Form type
4
Date filed
4/8/2025, 04:09 PM
Previous filing
Jul 10, 2024
Next filing
Aug 26, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Stock Option (Right to Buy) Award $0 +91K $0.00 91K Apr 4, 2025 Common Stock 91K $0.55 Direct F1
transaction STRO Restricted Stock Units (RSUs) Award $0 +84.5K $0.00 84.5K Apr 4, 2025 Common Stock 84.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.